Mirabegron Stada

Mirabegron, the active ingredient in Mirabegron Stada, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the treatment of overactive bladder symptoms such as urinary urgency, frequency, and urge incontinence in adults.

GNH USA supplies Mirabegron Stada as a licensed, GDP‑compliant international pharmaceutical product to hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support safe distribution across EU and global markets. Customers benefit from reliable supply chains and responsive technical support.

Mirabegron is used to manage symptoms of overactive bladder, a condition characterized by involuntary detrusor contractions.

- Overactive bladder: reduces urgency episodes and increases functional bladder capacity. - Urinary urgency: alleviates sudden, compelling urge to void. - Urinary frequency: decreases daytime voiding frequency, improving quality of life.

Common Side Effects: - Hypertension: elevated blood pressure may be observed. - Headache: mild to moderate intensity. - Nasopharyngitis: upper respiratory tract infection symptoms. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation. - Urinary retention: difficulty initiating urination.

Serious or Rare Side Effects: - Severe hypertension: markedly high blood pressure requiring medical attention. - Tachycardia: rapid heart rate. - Angioedema: swelling of face, lips, or throat. - Acute urinary retention leading to obstruction. - Allergic reactions: rash, pruritus, or anaphylaxis. - Myocardial infarction: rare cardiac events.

Before initiating therapy, clinicians should consider several safety aspects.

- Blood pressure assessment: measure baseline and monitor regularly. - Urinary retention monitoring: watch for signs of incomplete bladder emptying. - Concomitant antihypertensive review: adjust doses if needed. - Hepatic impairment: use with caution in severe liver disease. - Uncontrolled hypertension: avoid use in patients with markedly elevated BP. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Mirabegron may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase mirabegron exposure. - Strong CYP2D6 inducers (e.g., rifampin): reduce mirabegron effectiveness. - Anticholinergic agents: may exacerbate urinary retention.

Moderate Interactions (Monitor Closely):\n- Antihypertensives: possible reduction in blood‑pressure‑lowering effect. - Diuretics: may increase risk of hypertension. - NSAIDs: additive effect on blood pressure. - Beta‑blockers: potential for altered cardiovascular response. - Digoxin: monitor serum levels due to possible interaction.